fda glp-1 compounding enforcement news october 2025 February 17, 2026: Pennsylvania pharmacy earns another warning letter – Partnership for Safe Medicines Despite FDA crackdown, unapproved GLP-1s

Liraglutide (GLP1-agonist) showed no significant maternal to fetal transfer at least 3.5 hours after maternal exposure in a human study with one subject

Roos 2010

Thanks to Kamika Reynolds, Kim O'Malley, and Jason Roy for their invaluable contributions, and to the National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for supporting this work

& Minder, C

Focus on whole foods rich in protein, healthy fats, and complex carbohydrates to sustain energy throughout the day

Why Weight Is a Live Question in Lupus at All Weight gain is a familiar problem in lupus care, and glucocorticoid exposure is the most cited reason